Abstract

Quantifying drug-protein interactions has a pivotal role in both early phase drug development and clinical processes. Diverse affinity chromatographic methods like nonlinear chromatography can realize such quantification, however, their throughputs are challenged due to the loading of a single ligand during each run. This work derivatized a new equation for simultaneously determining the bindings of two ligands to a protein relying on assumption that the retention factors of the ligands are dependent on their injection amounts. Experimental validation of the derivatization was performed on an immobilized endothelin A receptor (ETAR) column taking ambrisentan, bosentan, and macitentan as injecting solutes. All three ligands presented a decrease in retention times along with increasing moles of injection when they were singly injected into the column. Likewise, negative relationships between the retentions and the injection amounts were observed when co-injection of ambrisentan/bosentan or bosentan/macitentan was performed, thus confirming the assumption of the derivatization. The association constants of ambrisentan, bosentan, and macitentan binding to ETAR were (1.42 ± 0.78)×104, (1.81 ± 0.22)×104, and (1.71 ± 0.41)×104 L/mol when each of them was singly loaded on the column. Such data displayed insignificant changes in four weeks thereby providing a proof of good stability of the column during the period. Co-injections of the two ligand pairs resulted in the association constants of (2.97 ± 0.13)×104 for ambrisentan, (2.51 ± 0.87)×104 for bosentan, and (2.88 ± 0.34)×104 L/mol for macitentan. These results were in good agreement with the calculation when each of the ligands was injected alone into the column and demonstrated little differences from the data by nonlinear chromatography. Owning to the simultaneous analysis of two ligands, the throughput of the proposed method was twofold higher than the typical assays including frontal analysis, zonal elution, and nonlinear chromatography. It is possible to become an alternative for rapid analysis of drug-protein interaction.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call